Want to see SRZN full AI Analyst Report?
Top Page
Surrozen
(NASDAQ:SRZN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$22.00
▼(-5.82% Downside)
Action:Reiterated
Date:08/07/26
SRZN scores low primarily due to very large losses, sustained cash burn, and negative equity that elevate financing and dilution risk. Technicals add modest pressure with the stock below key longer-term moving averages and a negative MACD. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Regenerative medicine focus
The company has a defined therapeutic focus around Wnt signaling, tissue repair, and regeneration rather than a broad or unfocused research strategy. Concentrating internal development on epithelial diseases may support specialized expertise and create opportunities for differentiated clinical programs over time.
Negative Factors
Extreme net losses
The very large TTM net loss demonstrates that Surrozen’s current operating cost base is far above its revenue level. Continued losses reduce financial resilience and mean that successful development, cost reduction, or additional funding will be needed before the business can approach sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Regenerative medicine focus
The company has a defined therapeutic focus around Wnt signaling, tissue repair, and regeneration rather than a broad or unfocused research strategy. Concentrating internal development on epithelial diseases may support specialized expertise and create opportunities for differentiated clinical programs over time.
Read all positive factors
Surrozen (SRZN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$267.51M
Dividend YieldN/A
Average Volume (3M)252.61K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue Growth-8.79%
EPS Growth-195.46%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume195,086
30 Day Avg. Volume252,608
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.00Price Target Upside84.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$10.93M
Surrozen Business Overview & Revenue Model
Company Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including dis...
How the Company Makes Money
Surrozen is not consistently revenue-generating from product sales because it is a clinical-stage biotech and, to the extent publicly available information indicates, does not have approved commercial therapeutics. The company’s funding and any re...
Surrozen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.51M | 3.48M | 10.65M | 0.00 | 12.50M | 0.00 |
| Gross Profit | 11.45M | 2.94M | 10.65M | -27.23M | 9.23M | -3.30M |
| EBITDA | -331.96M | -241.49M | -62.12M | -41.13M | -34.05M | -51.35M |
| Net Income | -332.13M | -242.03M | -63.56M | -43.04M | -36.00M | -52.51M |
Balance Sheet | ||||||
| Total Assets | 115.61M | 98.73M | 48.47M | 46.08M | 89.44M | 137.17M |
| Cash, Cash Equivalents and Short-Term Investments | 102.04M | 89.25M | 34.56M | 36.04M | 75.84M | 101.85M |
| Total Debt | 6.32M | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Total Liabilities | 334.27M | 286.49M | 69.85M | 8.14M | 13.43M | 27.47M |
| Stockholders Equity | -218.66M | -187.76M | -21.38M | 37.94M | 76.00M | 109.70M |
Cash Flow | ||||||
| Free Cash Flow | -34.98M | -30.37M | -17.65M | -40.76M | -44.87M | -50.08M |
| Operating Cash Flow | -34.76M | -30.24M | -17.63M | -40.36M | -44.15M | -48.81M |
| Investing Cash Flow | -222.00K | -128.00K | -26.00K | 51.72M | 38.31M | -77.71M |
| Financing Cash Flow | 46.58M | 85.05M | 16.18M | 276.00K | -2.56M | 124.63M |
Surrozen Technical Analysis
Negative
23.36
Price Trends
22.83
Negative
25.08
Negative
24.12
Negative
Market Momentum
-0.28
Positive
36.09
Neutral
22.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Negative. The current price of 23.36 is above the 20-day moving average (MA) of 23.32, above the 50-day MA of 22.83, and below the 200-day MA of 24.12, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 36.09 is Neutral, neither overbought nor oversold. The STOCH value of 22.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRZN.
Surrozen Risk Analysis
Surrozen disclosed 85 risk factors in its most recent earnings report. Surrozen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Surrozen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $681.47M | -12.75 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $546.83M | -5.73 | -23.64% | ― | -76.20% | 52.86% | |
52 Neutral | $388.52M | -3.42 | 1147.63% | ― | -36.09% | 24.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $166.49M | -1.45 | -123.53% | ― | -100.00% | 52.43% | |
49 Neutral | $147.14M | -3.89 | -171.19% | ― | ― | 83.55% | |
42 Neutral | $267.51M | -0.50 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
SRZN
Surrozen
20.68
8.98
76.75%
IRD
Opus Genetics
4.34
2.98
219.12%
OVID
Ovid Therapeutics
2.75
1.51
121.77%
STTK
Shattuck Labs
6.50
4.49
223.38%
SPRB
Spruce Biosciences
59.09
50.09
556.56%
BMEA
Biomea Fusion
1.93
0.07
3.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.